|Articles|November 9, 2021
- Pharmaceutical Executive-11-01-2021
- Volume 41
- Issue 11
Pharmaceutical Executive, November 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive November 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 4 years ago
In It For the Long-Haul: Planning for the Future of COVID-19over 4 years ago
Turning the Corner: A New Era of Pharma Sales Comes Into Viewover 4 years ago
The New COVID Workforce: Keeping Pharma Strong Through Adversityover 4 years ago
Crafting Curesover 4 years ago
Could 2022 Prove to Be Better Year for Biotech Companies?over 4 years ago
COVID and the Data Talent Turnaboutover 4 years ago
EU MEPs Arrive At Crossroads in Cancer Strategyover 4 years ago
Pharm Exec at 40 (2015-2018)Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
2
The Evolving Relationship Between FDA and Biotech
3
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
4
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
5